Catalyst Funds Management Pty Ltd Purchases 12,500 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Catalyst Funds Management Pty Ltd increased its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 2,083.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,100 shares of the biotechnology company’s stock after purchasing an additional 12,500 shares during the period. Catalyst Funds Management Pty Ltd’s holdings in Aldeyra Therapeutics were worth $65,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ALDX. Raymond James Financial Inc. bought a new stake in Aldeyra Therapeutics in the 4th quarter valued at $3,628,000. Jacobs Levy Equity Management Inc. increased its holdings in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after acquiring an additional 295,864 shares during the last quarter. Barclays PLC increased its holdings in Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 48,313 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in Aldeyra Therapeutics in the 4th quarter valued at $234,000. Finally, PDT Partners LLC bought a new stake in Aldeyra Therapeutics in the 3rd quarter valued at $169,000. 59.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a report on Monday, March 3rd.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX opened at $6.91 on Monday. Aldeyra Therapeutics, Inc has a 52 week low of $2.71 and a 52 week high of $7.20. The firm has a fifty day simple moving average of $5.79 and a two-hundred day simple moving average of $5.47. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). As a group, sell-side analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.